Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06084195
Recruiting Not applicable

Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging

NCT06084195 · tracked via the Priya Life Science France tracker
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Phase
Not applicable
Started
2023-12-19
Last updated
2025-02-12

Condition(s) studied

High Grade Serous Ovarian Cancer

Investigational drug(s) / intervention(s)

Blood sample and tissue sample

Blood sample and tissue sample: During the surgery : * Tissus sample : primary tumor and metastasis * blood sample : 3 EDTA tubes * ex vivo MRI data

Study summary

The objective of this study is to explore the integration of in vivo and ex vivo of MRI with histology and molecular assessments to advance non-invasive characterization of tumor heterogeneity in high-grade serous ovarian cance

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient aged \>18 * Pathologically proven HGSOC at an advanced stage (FIGO IIIB or IIIC) which can benefit from surgery with or without prior neoadjuvant treatment * Willingness and ability to comply with planned visits, treatment plan, laboratory tests and other study procedures, * Patient who has given informed, written and express consent, * Patient affiliated with a French health insurance scheme. Exclusion Criteria: * Early-stage disease (FIGO \<IIIB) or presence of extraperitoneal metastases, * Patient who will not have surgery * Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons, * Patient under guardianship, curatorship or safeguarding of justice, * Pregnant and/or nursing patient, * Patient with a history of other cancers within 5 years/10 years prior to inclusion

Primary outcome measure(s)

  • the integration of in vivo and ex vivo of MRI with histology and molecular assessments to advance non-invasive characterization of tumor heterogeneity in high-grade serous ovarian cancer. — one shoot at the surgery
    The diagnostic performance of the radiomic and multiomic algorithm for the characterization of heterogeneity in the CSOHG.

Trial sites (1)

FacilityCityRegionStatus
NOUGARET Stephanie Montpellier France Recruiting

More Institut du Cancer de Montpellier - Val d'Aurelle trials in France

Creation of a Clinical Database on Primary Nervous System Tumors Recruiting
Personalization of Breast Radiotherapy According to Loco-regional Recurrence Risk and Toxicity Probability Recruiting
Development of a Clinical and Biological Database in Peritoneal Carcinosis (BCB CARCINOSE) Recruiting
Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer Recruiting
Study of Sexual Quality of Life in Women With Breast Cancer Who Had Multidisciplinary Management With Photobiomodulation for Genitourinary Syndrome of the Menopause Recruiting

Other trials for the same condition

Routine Shallow-coverage Whole Genome Sequencing Testing of Liquid-based Cervical Smears for the Early Diagnosis of Ovarian Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06084195 on ClinicalTrials.gov ↗ ← All trials in France